EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSEEEG00000023124
Gene Symbol: MAP3K8
4 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSEEEG00000000573
Gene Symbol: MAP3K9
4 Cross references
196 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSEEEG00000021528
Gene Symbol: MGLL
4 Cross references
209 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSEEEG00000009232
Gene Symbol: NPR1A
4 Cross references
196 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSEEEG00000022824
Gene Symbol: NPR3
4 Cross references
210 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7

Ensembl ID : ENSEEEG00000019429
Gene Symbol: LOC113583653
3 Cross references
186 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSEEEG00000018388
Gene Symbol: LOC113577807
4 Cross references
208 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSEEEG00000004739
Gene Symbol: NPY2R
1 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSEEEG00000012126
Gene Symbol: NPY2RL
4 Cross references
178 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSEEEG00000007010
Gene Symbol: NTSR1
4 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSEEEG00000001980
Gene Symbol: NTRK2
1 Cross references
210 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSEEEG00000016399
Gene Symbol: NTRK3
4 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).